Berman Capital Advisors’s Voyager Therapeutics VYGR Stock Holding History

Berman Capital Advisors’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-85	Closed	–	–	2241
2021 Q2	$0	Buy	+85	New	+$385	﹤0.01%	2062

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Berman Capital Advisors's VYGR Position: Q3 2021 in Review

Berman Capital Advisors sold out of Voyager Therapeutics (VYGR) in Q3 2021, closing a stake of 85 shares.

Berman Capital Advisors first reported a position in VYGR in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 69 funds tracked by Wall St. Rank hold VYGR as of Q3 2021.

Berman Capital Advisors reported no remaining Voyager Therapeutics position as of Q3 2021 after selling out during the quarter.
Berman Capital Advisors sold 85 Voyager Therapeutics shares in Q3 2021.
Berman Capital Advisors first reported a position in Voyager Therapeutics in Q2 2021 and held it in 1 quarter.
Berman Capital Advisors's Voyager Therapeutics position peaked at $0 in Q2 2021.
69 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.